NEW YORK (GenomeWeb) – OpGen this week announced that it issued approximately 3.6 million shares of its common stock in the fourth quarter under its previously announced "at the market offering" program. The program has resulted in net proceeds of approximately $4.6 million, which will be used to support OpGen's research, development, and manufacturing of product candidates, and for other general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.